Dehydroepiandrosterone (DHEA) improves pulmonary hypertension in chronic obstructive pulmonary disease (COPD): A pilot study

Annales d'Endocrinologie

Volumn 73, Issue 1, 2012, Pages 20-25

  Dumas de La Roque, Eric ^a,e   Savineau, Jean Pierre ^a   Metivier, Anne Cécile ^b   Billes, Marc Alain ^c   Kraemer, Jean Philippe ^b   Doutreleau, Stéphane ^b   Jougon, Jacques ^c   Marthan, Roger ^a   Moore, Nicholas ^a   Fayon, Michael ^a   Baulieu, Étienne Émile ^d   Dromer, Claire ^c  

^a CENTRE DE RECHERCHE CARDIO THORACIQUE DE BORDEAUX   (France)

^b HÔPITAL CIVIL   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d Universite Paris Sud   (France)

^e HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBON MONOXIDE; DIURETIC AGENT; OXYGEN; PRASTERONE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG TOLERANCE; FEMALE; HUMAN; LUNG ARTERY PRESSURE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LUNG GAS EXCHANGE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; PILOT STUDY; PULMONARY HYPERTENSION; TREATMENT DURATION; TREATMENT OUTCOME; WALKING;

ADULT; DEHYDROEPIANDROSTERONE; EXERCISE TEST; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PILOT PROJECTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY GAS EXCHANGE; RESPIRATORY FUNCTION TESTS; VASCULAR RESISTANCE; WALKING;

EID: 84857503172     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2011.12.005     Document Type: Article

References (35)

1. Marthan R., Castaing Y., Manier G., Guenard H Gas exchange alterations in patients with chronic obstructive lung disease. Chest 1985, 87:470-475.
2. Barbera J.A., Blanco I. Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management. Drugs 2009, 69:1153-1171.
3. Burrows B., Kettel L.J., Niden A.H., Rabinowitz M., Diener C.F. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N Engl J Med 1972, 286:912-918.
4. Weitzenblum E., Hirth C., Ducolone A., Mirhom R., Rasaholinjanahary J., Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981, 36:752-758.
5. Traver G.A., Cline M.G., Burrows B. Predictors of mortality in chronic obstructive pulmonary disease. A 15-year follow-up study. Am Rev Respir Dis 1979, 119:895-902.
6. Barbera J.A. Nitric oxide in chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 1996, 51:528-532.
7. Archer S.L., Mike D., Crow J., Long W., Weir E.K. A placebo-controlled trial of prostacyclin in acute respiratory failure in COPD. Chest 1996, 109:750-755.
8. Stolz D., Rasch H., Linka A., Di Valentino M., Meyer A., Brutsche M., et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008, 32:619-628.
9. Blanco I., Gimeno E., Munoz P.A., Pizarro S., Gistau C., Rodriguez-Roisin R., et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2009, 181:270-278.
10. Zielinski J., Tobiasz M., Hawrylkiewicz I., Sliwinski P., Palasiewicz G. Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients: a 6-year prospective study. Chest 1998, 113:65-70.
11. Anthonisen N.R. Long-term oxygen therapy. Ann Intern Med 1983, 99:519-527.
12. Baulieu E.E., Corpechot C., Dray F., Emiliozzi R., Lebeau M.C., Mauvais Jarvis P., et al. An adrenal-secreted " androgen" : dehydroisoandrosterone sulfate. Its metabolism and a tentative generalization on the metabolism of other steroid conjugates in man. Recent Prog Horm Res 1965, 21:411-500.
13. Miller W.L. Androgen biosynthesis from cholesterol to DHEA. Mol Cell Endocrinol 2002, 198:7-14.
14. Belanger A., Candas B., Dupont A., Cusan L., Diamond P., Gomez J.L., et al. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab 1994, 79:1086-1090.
15. Labrie F., Belanger A., Cusan L., Gomez J.L., Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 1997, 82:2396-2402.
16. Baulieu E.E. Androgens and aging men. Mol Cell Endocrinol 2002, 198:41-49.
17. Barrett-Connor E., Khaw K.T., Yen S.S. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 1986, 315:1519-1524.
18. Bonnet S., Dumas-de-La-Roque E., Begueret H., Marthan R., Fayon M., Dos Santos P., et al. Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension. Proc Natl Acad Sci USA 2003, 100:9488-9493.
19. Barst R.J., McGoon M., Torbicki A., Sitbon O., Krowka M.J., Olschewski H., et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43:40S-47S.
20. Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., et al. Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
21. Redelmeier D.A., Bayoumi A.M., Goldstein R.S., Guyatt G.H. Interpreting small differences in functional status: the 6-minute-walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997, 155:1278-1282.
22. Guyatt G.H., Townsend M., Keller J., Singer J., Nogradi S. Measuring functional status in chronic lung disease: conclusions from a randomized control trial. Respir Med 1991, 85 Suppl. B:17-21. [discussion 33-17].
23. Rubin L.J., Badesch D.B., Barst R.J., Galie N., Black C.M., Keogh A., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896-903.
24. Nocturnal oxygen therapy trial group Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980, 93:391-398.
25. Timms R.M., Khaja F.U., Williams G.W. Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. Ann Intern Med 1985, 102:29-36.
26. Chang D.M., Lan J.L., Lin H.Y., Luo S.F. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:2924-2927.
27. Dumas de la Roque E., Savineau J.P., Bonnet S. Dehydroepiandrosterone: a new treatment for vascular remodeling diseases including pulmonary arterial hypertension. Pharmacol Ther 2010, 126:186-199.
28. Williams M.R., Dawood T., Ling S., Dai A., Lew R., Myles K., et al. Dehydroepiandrosterone increases endothelial cell proliferation in vitro and improves endothelial function in vivo by mechanisms independent of androgen and estrogen receptors. J Clin Endocrinol Metab 2004, 89:4708-4715.
29. Homma N., Nagaoka T., Karoor V., Imamura M., Taraseviciene-Stewart L., Walker L.A., et al. Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone. Am J Physiol Lung Cell Mol Physiol 2008, 295:L71-L78.
30. Dessouroux A., Akwa Y., Baulieu E.E. DHEA decreases HIF-1alpha accumulation under hypoxia in human pulmonary artery cells: potential role in the treatment of pulmonary arterial hypertension. J Steroid Biochem Mol Biol 2008, 109:81-89.
31. Bonnet S., Paulin R., Sutendra G., Dromparis P., Roy M., Watson K.O., et al. Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-{beta}/NFAT axis. Circulation 2009, 120:1231-1240.
32. D'Alonzo G.E., Barst R.J., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115:343-349.
33. Alp S., Skrygan M., Schmidt W.E., Bastian A. Sildenafil improves hemodynamic parameters in COPD - an investigation of six patients. Pulm Pharmacol Ther 2006, 19:386-390.
34. Madden B.P., Allenby M., Loke T.K., Sheth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul Pharmacol 2006, 44:372-376.
35. Rietema H., Holverda S., Bogaard H.J., Marcus J.T., Smit H.J., Westerhof N., et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 2008, 31:759-764.